PREMAS Biotech launched its suite of recombinant Human Cytochrome P450 Isozymes expressed in Saccharomyces cerevisiae.
The latest clinical trials, updates, orphan drug designations, and FDA approvals from pharma and biotech companies.
Thermo Fisher Scientific Inc. introduced the Thermo Scientific Nalgene Certified Clean PETG Containers.
Roche announced that it has increased its offer price for all outstanding publicly-held shares of Genentech.
By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy.
A recent study in Oregon suggests that drugs designed for treating the most severe mental illnesses are often prescribed at inappropriately low doses and at considerable expense, for use in conditions where their benefit has not been established.
Using a novel approach researchers has discovered new genes involved in Crohn's disease.
The combination of two drugs produces a critical improvement in the treatment of certain brain tumours.
The technology used to sequence the first genome 13 years is too slow and too costly by today’s standards. Fortunately, next-generation and third-generation sequencing technologies are competing for first place in the genomics marathon.
A clinical trial involving more than 3,000 women in the US and southern Africa demonstrates the promise of a vaginal microbicide gel for preventing HIV infection in women.
Scientists at the Sol Goldman Pancreatic Cancer Research Center at the Johns Hopkins Kimmel Cancer Center have used ‘personalized genome’ sequencing on an individual with a hereditary form of pancreatic cancer to locate a mutation in a gene called PALB2 that is responsible for initiating the disease.
Fish are helping researchers better understand how heart disease develops in studies that could lead to new drugs to slow disease and prevent heart attacks.
Symphogen A/S and Origen Therapeutics announced a strategic collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets.
Millennium Pharmaceuticals, Inc., announced that it has initiated two Phase 2 clinical trials of MLN8237.
In a collaborative study, researchers at the Stanford University School of Medicine have compiled a list of 93 common mutations of the AIDS virus associated with drug resistance that will be used to track future resistance trends throughout the world.